It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- Commercial-stage pharma dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company.
- Intercept system (flagship product) = reduces the risk of transfusion-transmitted infections
- Is the only pathogen reduction system with both CE mark and FDA approval for plasma and platelets
- The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US
- Furthermore, INTERCEPT® Fibrinogen Complex = FDA approved to treatment/control bleeding, including massive hemorrhage, due to fibrinogen deficiency